Aprea Therapeutics (APRE) Scheduled to Post Earnings on Thursday

Aprea Therapeutics (NASDAQ:APRE) will be posting its quarterly earnings results on Thursday, March 28th.

Aprea Therapeutics Trading Down 2.7 %

Shares of NASDAQ:APRE opened at $5.92 on Wednesday. Aprea Therapeutics has a 12 month low of $2.78 and a 12 month high of $8.85. The stock has a market cap of $22.14 million, a P/E ratio of -1.48 and a beta of 1.05. The company has a 50 day moving average of $6.35 and a 200 day moving average of $4.97.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Tuesday.

Insider Activity at Aprea Therapeutics

In other Aprea Therapeutics news, Director Bernd R. Seizinger bought 6,860 shares of Aprea Therapeutics stock in a transaction dated Wednesday, March 13th. The shares were purchased at an average cost of $7.29 per share, with a total value of $50,009.40. Following the completion of the purchase, the director now owns 33,685 shares of the company’s stock, valued at $245,563.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have acquired a total of 9,870 shares of company stock worth $71,952 in the last 90 days. Company insiders own 20.90% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

Several hedge funds have recently bought and sold shares of APRE. BNP Paribas Arbitrage SNC purchased a new position in shares of Aprea Therapeutics in the 3rd quarter worth about $40,000. Millennium Management LLC lifted its stake in shares of Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after buying an additional 43,293 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Aprea Therapeutics during the second quarter valued at approximately $54,000. Geode Capital Management LLC bought a new stake in shares of Aprea Therapeutics during the second quarter valued at approximately $74,000. Finally, Vanguard Group Inc. raised its holdings in Aprea Therapeutics by 76.4% in the 3rd quarter. Vanguard Group Inc. now owns 27,341 shares of the company’s stock worth $114,000 after acquiring an additional 11,840 shares during the last quarter. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.